Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05368805 · ClinicalTrials.gov registry record · Phase 1
Fruquintinib DDI Study With P-gp and BCRP Substrates
A Phase 1 study, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05368805 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 32 participants.
The verdict
NCT05368805, a Phase 1 study, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Fruquintinib DDI Study with P-gp and BCRP Substrates
Interventions
- DRUG Fruquintinib
- DRUG Rosuvastatin
- DRUG Dabigatran Etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05368805
The ClinicalTrials.gov registry entry for NCT05368805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fruquintinib is the first listed.
NCT05368805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05368805 about?
NCT05368805 is a clinical study titled "Fruquintinib DDI Study With P-gp and BCRP Substrates". Fruquintinib DDI Study with P-gp and BCRP Substrates
What is the current status of trial NCT05368805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-03-02. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT05368805?
The interventions under investigation include: Fruquintinib (DRUG), Rosuvastatin (DRUG), Dabigatran Etexilate (DRUG).
Who is sponsoring clinical trial NCT05368805?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.